China to Expand Reimbursement for Innovative Drugs

This signals a deliberate policy push toward broader state-backed adoption of innovative therapies, which could reshape demand dynamics for drugmakers and the broader healthcare supply chain. The focus on unifying reimbursement across regions reduces friction for both patients and manufacturers, potentially accelerating market access. The open question is how pricing negotiations will balance accessibility with profitability, and whether this expansion extends to cutting-edge modalities like cell or gene therapies, where cost pressures are most acute.